Introduction {#sec005}
============

Ovarian cancer is the fifth leading cause of cancer-related deaths among women in both developing and developed countries, and a substantial burden to global public health \[[@pone.0118872.ref001]\]. It is estimated that 50--60% of the deaths in ovarian cancer patients is linked to locally advanced disease \[[@pone.0118872.ref002]\]. Up to 10% of ovarian cancer patients are diagnosed with distant metastases, and the most common sites of organ metastases include breast, gastrointestinal tract and reproductive tract \[[@pone.0118872.ref002]\]. Despite the significant reduction in mortality rates of ovarian cancer patients over the past decades, the overall incidence rates continue to increase rapidly, even in countries that historically had low rates \[[@pone.0118872.ref003],[@pone.0118872.ref004]\]. Large population-based studies clearly indicated that current cytotoxic chemotherapy drugs are not effective in eliminating ovarian cancers, and combination therapy with itraconazole only marginally improves patient survival \[[@pone.0118872.ref005]\]. Therefore, it is extremely important to find effective ways to diagnose ovarian cancers at early stages, before the disease spreads locally or metastasizes to distant organs \[[@pone.0118872.ref006]\]. Angiogenesis is a crucial factor in tumor cell proliferation and metastatic dissemination in various human cancers, including ovarian cancers, therefore, a reliable assessment of tumor angiogenesis and micro-vessel density (MVD) in ovarian cancers is critical for correct prognosis of patients \[[@pone.0118872.ref007],[@pone.0118872.ref008]\].

Contrast-enhanced ultrasound (CEUS) is widely regarded as a reliable and convenient diagnostic imaging technique in ovarian cancer patients. CEUS, involves administration of micro-bubble contrast agents to reveal critical and sensitive information on tissue perfusion and blood flow, and is also effective in visualizing small arterial vessels less than 100 m in diameter. CEUS is considered as a relatively safe technique, and does not involve ionizing radiation or the risk of nephrotoxicity \[[@pone.0118872.ref009]--[@pone.0118872.ref012]\]. Unlike the color Doppler ultrasound, which is good at assessing large vascular networks in tumors, CEUS is better at interrogating tumor microvascularity, which is associated with slow blood flows and similar acoustic properties and thus, CEUS is a big advantage in diagnostics in ovarian cancers \[[@pone.0118872.ref013],[@pone.0118872.ref014]\]. CEUS also significantly improves the detection of microcirculation perfusion and previous studies showed that MVD difference is invaluable in evaluating benign and malignant ovarian cancers \[[@pone.0118872.ref015]\]. Further, several studies observed specific CEUS enhancements in different types and stages of ovarian cancer: ring-like enhancement seen in the ovarian cystic wall and ovarian cyst papillae in benign tumors; scattered mild enhancement and branching moderate enhancement observed in solid tumors \[[@pone.0118872.ref016],[@pone.0118872.ref017]\]; overall heterogeneous enhancement and rapidly increased enhancement in malignant ovarian cancer \[[@pone.0118872.ref018]\]. Consistent with this, several previous studies have found that CEUS can accurately distinguish benign ovarian tumor from malignant ovarian tumor \[[@pone.0118872.ref019]--[@pone.0118872.ref021]\], but other studies were unable to confirm the results. \[[@pone.0118872.ref022]\]. In order to comprehensively address this issue, we performed a systematical meta-analysis to assess the performance of CEUS in differential diagnosis of ovarian tumor mass.

Methods {#sec006}
=======

Data sources and keywords {#sec007}
-------------------------

To identify relevant published studies that evaluated the diagnostic value of CEUS in ovarian cancer, PubMed, Cochrane Library, CNKI databases (last updated search in November 1^st^, 2013) were comprehensively searched. Keywords used included "ovarian neoplasms" or "ovarian cancer" or "ovarian carcinoma" or "ovarian tumor" or "OC" for the diagnostic factors, and "contrast-enhanced ultrasound" or "contrast-enhanced ultrasonography" or "contrast ultrasonography" or "ultrasound contrast imaging" or "CEUS" for interventions. We also manually searched the bibliographies of prominent studies to identify additional relevant studies.

Inclusion and exclusion criteria {#sec008}
--------------------------------

The studies selected for the present meta-analysis fulfilled the following inclusion criteria: (1) the studies were clinical diagnostic test; (2) the studies addressed the accuracy of CEUS in differential diagnosis of malignant ovarian cancer and benign ovarian tumors; (3) all patients diagnosed with ovarian cancer were confirmed by histopathological examinations; (4) all lesion diagnosed were histologically confirmed after CEUS; (5) published data in the four-fold (2 × 2) tables must be sufficient. Studies that did not conform to the inclusion criteria were excluded from our meta-analysis. For duplicate studies, we only choose the latest or the study with largest sample size. The PRISMA Checklist is provided as supplementary information, see [S1 PRISMA Checklist](#pone.0118872.s001){ref-type="supplementary-material"}.

Data extraction {#sec009}
---------------

Two investigators separately collected information from eligible studies. The following data was collected: first author, publication year, study design, ethnicity, number of participant, age, gender and country, number of lesions, contrast agent and diagnostic accuracy.

Quality evaluation {#sec010}
------------------

Two or more investigators assessed the methodological quality in accordance with QUADAS (quality assessments of diagnostic accuracy studies) \[[@pone.0118872.ref023]\]. QUADAS covers 11 domains: whether representative spectrum is included (QUADAS01); whether reference standard is acceptable (QUADAS02); whether delay between tests is acceptable (QUADAS03); whether partial verification avoided (QUADAS04); whether differential verification avoided (QUADAS05); whether incorporation avoided (QUADAS06); whether reference standard results blinded (QUADAS07); whether index test results blinded? (QUADAS08); whether relevant clinical information is included (QUADAS09); whether uninterpretable results reported (QUADAS10); whether withdrawals were explained (QUADAS11).

Statistical analysis {#sec011}
--------------------

To calculate the effect size for each study, the pooled statistics for specificity (Spe), sensitivity (Sen), positive/negative likelihood ratios (LR^+^/LR^−^) as well as diagnostic odds ratio (DOR), and their 95% CIs, were utilized. In order to provide adequate evidence of all enrolled studies, as well as minimize the variance of the summary, Sen, Spe, LR^+^/LR^−^, and DOR with 95%CI were calculated. Random-effect model was employed if heterogeneity existed among the studies, otherwise fixed-effects model was utilized. The summary receiver operating characteristic (SROC) curve and the corresponding area under the curve (AUC) were obtained \[[@pone.0118872.ref024]\]. Threshold effect was assessed using Spearman correlation coefficients. The subgroup and meta-regression analyses were also carried out to explore potential sources of heterogeneity. Heterogeneity test was performed by the Cochran's *Q*-statistic \[[@pone.0118872.ref025]\]. *I* ^*2*^ test was further performed to assess the possibility of heterogeneity among studies \[[@pone.0118872.ref026]\]. Sensitivity analysis was conducted to assess whether the results were significantly affected via deleting a single study in the current meta-analysis. Publication bias was evaluated by using Deeks funnel plot and publication bias was further confirmed by Egger's linear regression analysis \[[@pone.0118872.ref026]\]. All tests in this meta-analysis were two-tailed and *P* \< 0.05 was regarded as statistically significant. The meta-analysis was performed using STATA version 12.0 (Stata Corp, College Station, TX, USA) and Meta-Disc version 1.4 (Universidad Complutense, Madrid, Spain).

Results {#sec012}
=======

Included studies {#sec013}
----------------

Initially, 294 studies were retrieved from electronic databases through keyword searches. After excluding duplicates, reviews, letters or meta-analyses, and studies not related to study topics, the remaining studies (n = 141) were reviewed and an additional 134 studies were excluded for being irrelevant to CEUS, or irrelevant to ovarian cancer. A total of 7 studies reported the correlation between CEUS and the diagnosis of ovarian cancer. Finally, these 7 high quality clinical trials, published between 2003 and 2013, were eligible for the present meta-analysis. \[[@pone.0118872.ref019]--[@pone.0118872.ref022],[@pone.0118872.ref027]--[@pone.0118872.ref029]\]. A total of 375 ovarian cancer patients were assessed in the seven studies, which included 198 malignant ovarian cancer patients and 177 patients with benign ovarian tumors. The sonographic contrast agent SonoVue was used in six studies, and one study used Levovist. Transabdominal ultrasound was performed in 3 studies and transvaginal ultrasound was done in 4 studies. GE Logiq ultrasound system was used in 4 studies, Philips iU22 ultrasound system in 2 studies and ALT Ultramark ultrasound system was used in the remaining 1 study. Of the included clinical trials, 4 trials used second harmonic imaging (SMI), 3 trials applied pulse inversion harmonic imaging (PIHI). Study subjects, study baseline characteristics and methodological qualities are showed in [Table 1](#pone.0118872.t001){ref-type="table"} and Fig. [1](#pone.0118872.g001){ref-type="fig"}, [2](#pone.0118872.g002){ref-type="fig"}, respectively.

![Risk of bias summary: review authors\' judgments about each risk of bias item for each included study.](pone.0118872.g001){#pone.0118872.g001}
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###### Baseline characteristics and methodological quality of all included studies.

![](pone.0118872.t001){#pone.0118872.t001g}

  First                                 Year   Sample   size   Age          Tumor size   \(cm\)     Route            Instrument      Contrast agent   Modality   2×2 table           
  ------------------------------------- ------ -------- ------ ------------ ------------ ---------- ---------------- --------------- ---------------- ---------- ----------- --- --- ----
  Zhang Y \[[@pone.0118872.ref020]\]    2013   25       23     40.0±11.0    7.3±3.6                 Transvaginal     GE Logiq        SonoVue          SMI        24          1   1   22
  Yang F \[[@pone.0118872.ref028]\]     2013   75       31     44.4±12.8    9.1±5.7      7.8±3.3    Transvaginal     Philips iU22    SonoVue          PIHI       70          3   5   28
  Wang XT \[[@pone.0118872.ref019]\]    2012   20       29     40.3±12.2    3.5∼11.2                Transabdominal   Philips iU22    SonoVue          PIHI       19          2   1   27
  Zheng QC \[[@pone.0118872.ref029]\]   2011   14       22     41 (23∼76)   1.2∼6.9      0.8∼9.6    Transabdominal   GE Logiq        SonoVue          SMI        14          2   0   20
  Hassan M \[[@pone.0118872.ref027]\]   2011   22       30     45 (18∼76)   7.5 ± 4.6    7.5±3.9    Transvaginal     GE Logiq        SonoVue          SMI        22          5   0   25
  Zhou Q \[[@pone.0118872.ref021]\]     2009   30       35     42.0±14.0    0.8∼9.6      3.5∼15.2   Transabdominal   GE Logiq        SonoVue          SMI        29          1   1   34
  Gu WR \[[@pone.0118872.ref022]\]      2003   12       7      42.2±10.1    5.8±2.0      5.8±1.5    Transvaginal     ALT Ultramark   Levovist         PIHI       12          2   0   5

Legend: TP---true positive; TN---true negative; FP---false positive; FN---false negative; SMI---second harmonic imaging; PIHI, pulse inversion harmonic imaging.

Quantitative data synthesis {#sec014}
---------------------------

The diagnostic accuracy of CEUS in discriminating between malignant ovarian cancer and benign ovarian tumor was measured as pooled Sen, Spe, LR^+^, LR^−^ and DOR ([Fig. 3](#pone.0118872.g003){ref-type="fig"}). Random effects model was used due to the existence of significant heterogeneity among studies([Fig. 4](#pone.0118872.g004){ref-type="fig"}). Our meta-analysis revealed that CEUS enhancement pattern of malignant ovarian cancer was centrifugal stability enhancement, and benign ovarian tumors showed an annular enhancement, and the pooled Sens was 0.96 (95%CI = 0.92∼0.98) and the pooled Spes was 0.91 (95%CI = 0.86∼0.94) in malignant ovarian cancers. There was no significant association (*r* = −0.505, *P* = 0.414) between sensitivity and specificity, which indicated the absence of threshold effect. In addition, we observed that the pooled LR^+^ and LR^−^ were 10.63 (95%CI = 6.59∼17.17) and 0.04 (95%CI = 0.02∼0.09), respectively. The pooled DORs of CEUS in qualitative diagnosis of ovarian cancer was 241.04 (95%CI = 92.61∼627.37). The results were plotted as a symmetrical SROC curve and the corresponding AUC was 0.98 (95%CI = 0.20∼1.00), suggesting a moderate diagnostic value ([Fig. 5](#pone.0118872.g005){ref-type="fig"}). Pooled likelihood ratio analysis indicated the limited diagnosis value of CEUS in differential diagnosis of benign and malignant ovarian tumors ([Fig. 6](#pone.0118872.g006){ref-type="fig"}). The results of Fagan's Nomogram indicated that pretest probability ratio is 20%, the post-test probability for LR+ is 73%, for LR− is 1% ([Fig. 7](#pone.0118872.g007){ref-type="fig"}). Meta-regression analysis showed that, route, modality, sample size and publication year were not the main factors influencing the heterogeneity for Sen; while for Spe, route may be the main source of heterogeneity ([Table 2](#pone.0118872.t002){ref-type="table"} and [Fig. 8](#pone.0118872.g008){ref-type="fig"}).

![Bivariate Boxplot for contrast-enhanced ultrasonography (CEUS) in differential diagnosis for benign and malignant ovarian tumors.](pone.0118872.g003){#pone.0118872.g003}

![Forest plot of specificity (Spe), sensitivity (Sen), positive and negative likelihood ratios (LR^+^/LR^−^), and diagnostic odds ratio (DOR) with their 95%Cis for contrast-enhanced ultrasonography (CEUS) in differential diagnosis for benign and malignant ovarian tumors.](pone.0118872.g004){#pone.0118872.g004}

![The summary receiver operating characteristic (SROC) curve for contrast-enhanced ultrasonography (CEUS) in differential diagnosis for benign and malignant ovarian tumors.](pone.0118872.g005){#pone.0118872.g005}

![Likelihood ratios plot for contrast-enhanced ultrasonography (CEUS) in differential diagnosis for benign and malignant ovarian tumors.](pone.0118872.g006){#pone.0118872.g006}

![Fagan's Nomogram plot for contrast-enhanced ultrasonography (CEUS) in differential diagnosis for benign and malignant ovarian tumors.](pone.0118872.g007){#pone.0118872.g007}

![Meta-regression plot for contrast-enhanced ultrasonography (CEUS) in differential diagnosis for benign and malignant ovarian tumors.](pone.0118872.g008){#pone.0118872.g008}
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###### Meta-regression analyses of potential source of heterogeneity.

![](pone.0118872.t002){#pone.0118872.t002g}

  Parameter        category       Number of studies   Sensitivity        p1     Specificity        p2
  ---------------- -------------- ------------------- ------------------ ------ ------------------ ------
  Route            Transvaginal   4                   0.96(0.92--0.99)   0.28   0.88(0.81--0.95)   0
  Transabdominal   3              0.97(0.93--1.00)    0.94(0.89--0.99)                             
  Modality         SMI            4                   0.98(0.95--1.00)   0.63   0.92(0.86--0.97)   0.18
  PIHI             3              0.94(0.90--0.99)    0.89(0.82--0.97)                             
  Sample size      \< 50          4                   0.97(0.93--1.00)   0.94   0.91(0.85--0.97)   0.05
  ≥ 50             3              0.95(0.92--0.99)    0.91(0.85--0.96)                             
  Year             ≥ 2010         5                   0.96(0.92--0.99)   0.71   0.90(0.85--0.95)   0.11
  \< 2010          2              0.98(0.93--1.00)    0.93(0.85--1.00)                             

SMI---second harmonic imaging; PIHI, pulse inversion harmonic imaging.

Sensitivity Analysis and Publication Bias {#sec015}
-----------------------------------------

Sensitivity analysis demonstrated that no single study had marked effect on the overall effect sizes ([Fig. 9](#pone.0118872.g009){ref-type="fig"}). The included angle between regression line and DOR axis was close to 90° in deeks funnel plot, and illustrated minimal publication bias in current meta-analysis ([Fig. 10](#pone.0118872.g010){ref-type="fig"}). Egger's linear regression analysis further confirmed that no publication bias existed among the included studies (t = −0.52, P = 0.626).

![Sensitivity analysis for contrast-enhanced ultrasonography (CEUS) in differential diagnosis for benign and malignant ovarian tumors.](pone.0118872.g009){#pone.0118872.g009}

![Deeks funnel plot for contrast-enhanced ultrasonography (CEUS) in differential diagnosis for benign and malignant ovarian tumors.](pone.0118872.g010){#pone.0118872.g010}

Discussion {#sec016}
==========

CEUS requires the administration of ultrasound contrast agents, which generally containsgas-filled micro-bubbles with a stabilized shell, small enough to pass through the blood vessels when administered intravenously \[[@pone.0118872.ref030]\]. Technological advances have allowed rapid expansion in the clinical application of CEUS \[[@pone.0118872.ref031]\], and recently, CEUS was used to differentiate benign ovarian tumors from malignant ovarian cancers \[[@pone.0118872.ref032]\]. CEUS has the capability to clearly display microvascular blood flow in tumors, and can accurately evaluate the sequence and intensity of tumor perfusion and vascularity. Not surprisingly, CEUS is already regarded as a superior technique for diagnosis of malignant ovarian cancers at early stages \[[@pone.0118872.ref033]\]. In addition, CEUS can detect the differences in microcirculations between benign and malignant tumors, and is able to qualitatively diagnose different types of lesions. Therefore, CEUS could become a valuable diagnostic tool for screening high-risk populations for ovarian cancers \[[@pone.0118872.ref021]\].

The technical performance and detection accuracy of CEUS in differential diagnosis of benign and malignant ovarian tumors was carefully evaluated in this meta-analysis. We extracted data from seven independent high quality studies containing a total of 198 malignant ovarian cancer patients and 177 benign ovarian tumor patients. Our results showed that the pooled Sen, Spe and DOR of CEUS in diagnosing ovarian cancer were 96%, 91% and 212.18, respectively. These results demonstrated the high diagnostic accuracy and detection efficiency of CEUS for ovarian cancer. One possible explanation for the high specificity could be that the CEUS contrast agent inherently prevents false sonographic images and the micro-bubbles offers superior technical capabilities in differentiating ovarian cancers even from small blood vessels, slow blood flows and similar acoustic properties, thereby resulting in improved diagnostic accuracy \[[@pone.0118872.ref013],[@pone.0118872.ref034]\]. Our findings showed no significant relationship between Sen and Spe, revealing no evidence of threshold effect within the selected studies, which refers to sudden and radical change after a quantitative limit is exceeded. Importantly, the existence of a threshold divides a group into two sub-groups, one above the threshold and one below the threshold \[[@pone.0118872.ref035]\]. Meta-regression analyses showed the differences in sample size, route and instrument type did not influence the CEUS diagnostic accuracy, indicating that CEUS exhibited a high diagnostic performance in different subgroups. Furthermore, our results found no direct evidence of publication bias. Our results are partly consistent with previous studies, and strongly support the high accuracy of CEUS in differential diagnosis of benign and malignant ovarian tumors.

Our present meta-analysis is the first to focus on the accuracy of CEUS in distinguishing malignant ovarian tumors from benign lesions. However, our study has limitations. First, due to the relatively small sample size (n = 7, with a total sample size of 375), insufficient statistical power may restrict our ability to evaluate the accuracy of CEUS. In addition, this meta-analysis was retrospective, which may strongly influence the results due to selection bias. Third, important data from the present publications and original authors was unavailable, therefore, data extraction was difficult, which may have adversely effected the clinical assessment of CEUS for its value indiagnosis of ovarian cancer. Fourth, we did not compare the diagnostic performance of CEUS with other imaging tools used for distinguishing between benign and malignant ovarian tumors.

In conclusion, our results strongly support the high diagnostic value of CEUS in differential diagnosis of benign and malignant tumors in ovarian cancer patients. CEUS may be an effective tool for detection of early stage ovarian cancers. However, further studies are required in a larger sample size and in diverse ethnic populations to fully confirm our findings.
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